| Literature DB >> 30443190 |
Jianle Wang1,2, Ke Wang1,2, Chongan Huang1,2, Dongdong Lin1,3, Yifei Zhou1,2,4, Yaosen Wu1,2,4, Naifeng Tian1,2,4, Pei Fan1, Xiangxiang Pan1,2, Daoliang Xu1, Jianing Hu4, Ying Zhou4, Xiangyang Wang1,2,4, Xiaolei Zhang1,2,5,4.
Abstract
Mitochondrial dysfunction is an important contributor to the development of osteoarthritis (OA). Sirtuin 3 (SIRT3) regulates diverse mitochondrial proteins to maintain mitochondrial homeostasis, and dihydromyricetin (DHM) is reported as a potential SIRT3 activator. This study aims to explore the relevance of SIRT3 and OA, as well as the therapeutic effects of DHM on mitochondrial homeostasis in TNF-α-treated chondrocytes. The relationship between SIRT3 and OA was confirmed by detecting SIRT3 level in vitro and in vivo. Mitochondrial dysfunction was evaluated in chondrocytes with or without SIRT3 knockdown. Furthermore, the effects of DHM on mitochondrial homeostasis were performed in TNF-α-treated rat chondrocytes in vitro. In this study, our results showed that the SIRT3 level was decreased in mouse OA cartilage, corresponding to the reduced SIRT3 level in TNF-α-treated chondrocytes in vitro. SIRT3 knockdown induced mitochondrial dysfunction in chondrocytes. Moreover, our study demonstrated that DHM might activate SIRT3 to protect rat chondrocytes from TNF-α-induced degeneration and protective effects of DHM on mitochondrial homeostasis in chondrocytes attributed to enhanced SIRT3. Collectively, SIRT3 deficiency is implicated in OA development and DHM exerts anti-degeneration effect by maintaining mitochondrial homeostasis via a SIRT3-dependent manner in chondrocytes.Entities:
Keywords: Dihydromyricetin; SIRT3; mitochondria; osteoarthritis
Mesh:
Substances:
Year: 2018 PMID: 30443190 PMCID: PMC6231225 DOI: 10.7150/ijbs.27746
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Figure 1SIRT3 decreases in mouse OA cartilage and TNF-α-treated rat chondrocytes (A, B) Double meniscus destabilization resulted in articular cartilage necrosis and thining. Scale bar 50 μM. (C) Immunofluorescence staining of SIRT3 in rat knee articular cartilage from sham group and OA group. (D, E) SIRT3 levels of chondrocytes from human cartilage. (F, G) The level of SIRT3 in chondrocytes treated with different concentrations of TNF-α for 24 h. (H, I) The level of SIRT3 in chondrocytes treated with TNF-α (50 ng/ml) for increasing time (0, 6 h, 12 h and 24 h). All experiments were performed as mean ± SD of 5 times in duplicates. *P < 0.05, **P < 0.01.
Figure 2SIRT3 knockdown impairs mitochondrial dysfunction induced by TNF-α in rat chondrocytes. (A, B) Rats chondrocytes was transfected with scramble lentivirus and SIRT3 knockdown lentivirus. Representative Western blots of and quantitative data for SIRT3 level in each group. (C, D) The effect of SIRT3 knockdown on the mitochondrial membrane potential in chondrocytes. (E) SIRT3 knockdown promoted the translocation of p53 to mitochondria in TNF-α-treated chondrocytes. (F) The effect of SIRT3 knockdown on ATP production in chondrocytes. All experiments were performed as mean ± SD of 5 times in duplicates. *P < 0.05, **P < 0.01.
Figure 3DHM maintains the balance between the anabolism and catabolism of ECM in TNF-α-treated chondrocytes. (A) The effect of DHM on viability of rat chondrocytes. (B, C) DHM promotes the level of SIRT3 in chondrocytes. (D-I) Representative western blots of and quantitative data for SIRT3, aggrecan, collagen II, ADAMTS-5 and MMP-13 levels in each group. All experiments were performed as mean ± SD of 5 times in duplicates. *P < 0.05, **P < 0.01.
Figure 4DHM promotes the capacity of anti-oxidation via activating SIRT3 in rat chondrocytes. (A, B) Representative micrographs of MitoSOX assay showed the effects of DHM on the ROS level in chondrocytes against TNF-α. Scale bar 100 μM.(C, D) Representative western blots and results of densitometry analysis of acetyl-k68 MnSOD in rat chondrocytes treated as above. (E) DHM promoted the activity of MnSOD via enhancing SIRT3 in chondrocytes. All experiments were performed as mean ± SD of 5 times in duplicates. *P < 0.05, **P < 0.01.
Figure 5DHM alleviates the mitochondrial dynamic imbalance through enhancing SIRT3. (A, B) The effects of DHM on mitochondrial dynamics markers in chondrocytes. Representative western blots of and quantitative data for DRP1, MFN2 and FIS1 levels of chondrocytes in each group. (C, D) Activation of SIRT3 by DHM promoted mitochondrial fission and fusion against TNF-α. All experiments were performed as mean ± SD of 5 times in duplicates. *P < 0.05, **P < 0.01.
Figure 6DHM promotes mitophagy via up-regulating SIRT3 in rat chondrocytes treated with TNF-α. (A, B) The effects of SIRT3 on levels of NIX and BNIP3. Representative western blots of and quantitative data for NIX and BNIP3 levels in each group. (C) DHM induced more co-localization of LC3 and NIX via activating SIRT3 in chondrocytes. Immunofluorescent signals were labeled by LC3 (green) and NIX (red). All experiments were performed as mean ± SD of 5 times in duplicates. *P < 0.05, **P < 0.01.
Figure 7SIRT3 is regulated through AMPK-PGC-1α-SIRT3 signaling pathway in chondrocytes treated with DHM. (A, B) DHM up-regulated the ratio of p-AMPK to AMPK as well as levels of PGC-1α and SIRT3 as a dose-dependent manner. Representative western blots of and quantitative data for p-AMPK/AMPK, PGC-1α and SIRT3 levels in chondrocytes from each group. (C, D) Effects of compound C on levels of AMPK-PGC-1α-SIRT3 signaling pathway in chondrocytes treated with DHM. (E, F) Effects of PGC-1α on SIRT3 in chondrocytes treated with DHM. All experiments were performed as mean ± SD of 5 times in duplicates. *P < 0.05, **P < 0.01.